Adimab, LLC 3
3 · Adagio Therapeutics, Inc. · Filed Aug 5, 2021
Insider Transaction Report
Form 3
Adimab, LLC
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (25,000,000 underlying)Series C Preferred Stock
→ Common Stock (640,320 underlying)- 1,985,295
Common Stock
Series B Preferred Stock
→ Common Stock (220,380 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into 5 shares of Common Stock, has no expiration date and is expected to automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.